{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T19:05:26Z","timestamp":1774551926610,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ajog.2015.10.148","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T15:44:33Z","timestamp":1446219873000},"page":"536.e1-536.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort"],"prefix":"10.1016","volume":"214","author":[{"given":"Amy L.","family":"Turitz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie A.","family":"Bastek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Purisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal A.","family":"Elovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa D.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2015.10.148_bib1","first-page":"1","article-title":"Births: preliminary data for 2012","volume":"62","author":"Hamilton","year":"2013","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.ajog.2015.10.148_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/01.AOG.0000275287.08520.4a","article-title":"Prediction and prevention of recurrent spontaneous preterm birth","volume":"110","author":"Spong","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib3","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa035140","article-title":"Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate","volume":"348","author":"Meis","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2015.10.148_bib4","first-page":"1115","article-title":"Use of progesterone to reduce preterm birth. ACOG Committee opinion","volume":"102","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1097\/AOG.0b013e31818b1ff6","article-title":"Use of progesterone to reduce preterm birth. ACOG Committee opinion no. 419","volume":"112","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2012.03.010","article-title":"Progesterone and preterm birth prevention: translating clinical trials data into clinical practice","volume":"206","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.AOG.0000160432.95395.8f","article-title":"17 Hydroxyprogesterone for the prevention of preterm delivery","volume":"105","author":"Meis","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib8","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ajog.2006.06.034","article-title":"Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: a 2005 follow-up survey","volume":"195","author":"Ness","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/s-0032-1311979","article-title":"Pregnancy outcomes of women\u00a0receiving compounded 17 alpha-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011","volume":"29","author":"Sibai","year":"2012","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2015.10.148_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s40261-013-0099-4","article-title":"A\u00a0national survey examining obstetrician perspectives on use of 17-alpha hydroxyprogesterone caproate post-US FDA approval","volume":"33","author":"Rebarber","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ajog.2015.10.148_bib11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000150560.24297.4f","article-title":"Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States","volume":"105","author":"Petrini","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib12","doi-asserted-by":"crossref","first-page":"375.e1","DOI":"10.1016\/j.ajog.2009.08.015","article-title":"Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length","volume":"201","author":"Owen","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib13","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.286.11.1340","article-title":"Mid-trimester endovaginal sonography in women at high risk for spontaneous preterm birth","volume":"286","author":"Owen","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2015.10.148_bib14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1067\/mob.2000.106851","article-title":"Patients with an ultrasonographic cervical length \u226415 mm have nearly a 50% risk of early spontaneous preterm delivery","volume":"182","author":"Hassan","year":"2000","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib15","first-page":"55","article-title":"Spontaneous preterm birth in African-American and Caucasian women receiving 17\u03b1-hydroxyprogesterone caproate","volume":"31","author":"Timofeev","year":"2014","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2015.10.148_bib16","doi-asserted-by":"crossref","first-page":"40.e1","DOI":"10.1016\/j.ajog.2011.03.028","article-title":"Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation","volume":"205","author":"Caritis","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2015.10.148_bib17","doi-asserted-by":"crossref","first-page":"135.e1","DOI":"10.1016\/j.ajog.2011.03.048","article-title":"Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate","volume":"205","author":"Manuck","year":"2011","journal-title":"Am J Obstet Gynecol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937815014532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937815014532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:08:18Z","timestamp":1757588898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937815014532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0002937815014532"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2015.10.148","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient characteristics associated with 17-alpha hydroxyprogesterone caproate use among a high-risk cohort","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2015.10.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}